Clinical trials: Rosai Dorfman Disease
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Erdheim-Chester Disease
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes.
- Trial name
- NCT03329274
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Histiocytosis
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.
- Trial name
- NCT03127709
- Testing
- Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG)
Mirdametinib in Histiocytic Disorders
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
- Conditions
- Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
- Trial name
- NCT06153173
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment.
- Conditions
- Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NACHO-COBI (NCT04079179)
- Testing
- Cobimetinib
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Carl Allen
Rosai-Dorfman Disease
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is mostly based on retrospective study.
- Trial name
- NCT04924647
- Testing
- lenalidomide and dexamethasone
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Peking Union Medical College Hospital
Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD)
International Rare Histiocytic Disorders Registry (IRHDR)
The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease that resolves spontaneously, to progressive disseminated forms that…
- Conditions
- Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD), Rosai-Dorfman Disease (RDD), Xanthogranuloma Family (XG)
- Trial name
- IRHDR (NCT02285582)
- Testing
- Registry study
- Where
- 15 sites in United States, Argentina and 7 more
- Volunteers
- 400 people
- Sponsor
- The Hospital for Sick Children
Histiocytosis, Langerhans Cell Histiocytosis
Histiocytic Disorder Follow-up Study
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific…
- Conditions
- Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NCT05915208
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- University of Alabama at Birmingham
Rosai-Dorfman Disease
Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease
In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
- Trial name
- NCT07187167
- Testing
- Lenalidomide, Dexamethasone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Hodgkin Lymphoma, Multiple Myeloma
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and…
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease
- Trial name
- NCT05093335
- Testing
- [68Ga]-Pentixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rosai-Dorfman Disease, Langerhans Cell Histiocytosis
Central China Rosai-Dorfman Disease Registry
This is a research study among patients with Rosai-Dorfman disease.
- Trial name
- CCR-DDR (NCT05284942)
- Testing
- Mycophenolate mofetil combined with oral prednisone
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Tongji Hospital